Atypical kinetic profiles in drug metabolism reactions

Drug Metabolism and Disposition

Volumn 30, Issue 4, 2002, Pages 355-362

  Hutzler, J Matthew ^a   Tracy, Timothy S ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; BENZYLOXYRESORUFIN; CELECOXIB; CYTOCHROME P450; DAPSONE; DEXTROMETHORPHAN; DIAZEPAM; DRUG; ESTRADIOL; ETHOXYRESORUFIN; FLUOXETINE; HALOTHANE; PARACETAMOL; PROGESTERONE; QUINIDINE; TENOXICAM; TESTOSTERONE; TRIAZOLAM; UNCLASSIFIED DRUG;

DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVATION; LIVER MICROSOME; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PORTRAITS;

EID: 0036201594     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.4.355     Document Type: Short Survey

References (62)

1. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms
2. Allosteric behavior in cytochrome P450-dependent in vitro drug-drug interactions: A prospective based on conformational dynamics
3. Kinetic studies of hepatocytes UDP-glucuronosyltransferase: Evidence of an allosteric enzyme
4. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity
5. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: Role in steroid hydroxylase activity and a-naphthoflavone stimulation
6. Autoactivation and activation of the cytochrome P450s
7. Further characterization of the expression in liver and catalytic activity of CYP2B6
8. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin
9. 5 with cytochromes P4503A4 and P45017A: Relevance of heme transfer reactions
10. Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics
11. Elucidation of distinct ligand binding sites for cytochrome P450 3A4
12. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model
13. Studies on the mechanism of activation of microsomal benzo[α]pyrene hydroxylation by flavonoids
14. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone
15. Dapsone activation of CYP2C9-mediated metabolism: Evidence for activation of multiple substrates and a two-site model
16. Biphasic kinetic behavior of rat cytochrome P4501A1-dependent monooxygenation in recombinant yeast microsomes
17. Activation of monooxygenases in human liver by 7,8-benzoflavone
18. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates
19. Multisite kinetic models for CYP3A4: Simultaneous activation and inhibition of diazepam and testosterone metabolism
20. CO binding kinetics of human cytochrome P450 3A4: Specific interaction of substrates with kinetically distinguishable conformers
21. Differential mechanisms of cytochrome P450 inhibition and activation by α-naphthoflavone
22. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
23. In vivo activation of zoxazolamine metabolism by flavone
24. In vitro and in vivo activation of oxidative drug metabolism by flavonoids
25. Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes
26. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions
27. Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4
28. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro
29. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone
30. Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: Evidence for two binding sites
31. Activation of phenacetin O-deethylase activity by a-naphthoflavone in human liver microsomes
32. In vitro stimulation of warfarin metabolism by quinidine: Increases in the formation of 4′- and 10-hydroxywarfarin
33. Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine
34. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol
35. Metabolism of levo-α-acetylmethadol (LAAM) by human liver cytochrome P450: Involvement of CYP3A4 characterized by atypical kinetics with two binding sites
36. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P450 2C9-reconstituted system
37. Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine
38. 2+
39. Triazolam substrate inhibition: Evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site
40. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone
41. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4
42. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site
43. Enzyme kinetics of cytochrome P450-mediated reactions
44. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: An example of the metabolism of diazepam and its derivatives
45. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro
46. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochrome P450
47. Substrate-dependent modulation of CYP3A4 catalytic activity analysis of 27 test compounds with four fluorometric substrates
48. Molecular basis of P450 inhibition and activation: Implications for drug development and drug therapy
49. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor
50. Interaction of diclofenac and quinidine in monkeys: Stimulation of diclofenac metabolism
51. Roles of human hepatic cytochrome P450 2C9 and 3A4 in the metabolic activation of diclofenac
52. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F1141 active site mutation of CYP2C9: Effect on atypical kinetic metabolism profiles
53. Cooperativity in oxidations catalyzed by cytochrome P450 3A4
54. Microsomal binding of amitriptyline: Effect on estimation of enzyme kinetic parameters in vitro
55. Human cytochrome P450 3A4 In vitro drug-drug interaction patterns are substrate-dependent
56. Human cytochrome P450 3A4-catalyzed testosterone 6β-hydroxylation and erythromycin N-demethylation
57. Aryl hydrocarbon (benzo[α]pyrene) hydroxylases in liver from rats of different age, sex, and nutritional status
58. Aryl hydrocarbon (benzo[α]pyrene) hydroxylase in microsomes from rat tissues: Differential inhibition and stimulation by benzoflavones and organic solvents
59. Sigmoidal kinetics of CYP3A substrates: An approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat
60. The human hepatic cytochrome P450 involved in drug metabolism
61. 5 in stimulation of catalytic activities of cytochrome P450 3A4
62. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450